Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial.
The Lancet Oncology.
Times cited: 118
Improved survival with bevacizumab in advanced cervical cancer.
New England Journal of Medicine.
Times cited: 572
Sexual function of patients with endometrial cancer enrolled in the Gynecologic Oncology Group LAP2 study.
International Journal of Gynecological Cancer.
Times cited: 20